Search results for "RADIOTHERAPY"

showing 10 items of 473 documents

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy aft…

2016

Tumor immunologic microenvironment is strongly involved in tumor progression and the presence of tumor infiltrating lymphocytes (TIL) with different phenotypes has been demonstrated to be of prognostic relevance in different malignancies. We investigated whether TIL infiltration of tumor tissues could also predict the outcome of prostate cancer patients. To this end, we carried out a retrospective analysis correlating the outcome of locally advanced prostate cancer patients undergone salvage radiotherapy upon relapse after radical surgery with the infiltration by different TIL populations. Twenty-two patients with resectable prostate cancer, with a mean age of 67 (+/−3.93) years, who receiv…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorChemokyne Receptor 7Prostate cancer0302 clinical medicineRecurrencePD-1Tumor MicroenvironmentForkhead Transcription Factorshemic and immune systemsprostate cancerPrimary tumorChemokyne Receptor 7; disease-free survival; FoxP3; overall survival; PD-1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytesOncologytumor infiltrating lymphocytes030220 oncology & carcinogenesisMolecular MedicineprognosiResearch PaperReceptors CCR7medicine.medical_specialtydisease-free survivaloverall survivalchemical and pharmacologic phenomena03 medical and health sciencesLymphocytes Tumor-InfiltratingMedian follow-upFoxP3Internal medicineChemokyne Receptor 7; disease-free survival; FoxP3; overall survival; PD-1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytes; Molecular Medicine; Oncology; Pharmacology; Cancer ResearchT regulators lymphocytesmedicineHumansProgression-free survivalRadical surgeryradiotherapyAgedSalvage TherapyPharmacologybusiness.industryTumor-infiltrating lymphocytesProstatic Neoplasmsmedicine.diseaseRadiation therapyT regulators lymphocyte030104 developmental biologyTumor progressionprognosistumor infiltrating lymphocytebusinessCancer Biology & Therapy
researchProduct

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?

2018

The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and expert discussion, Professor Cervantes summarizes the findings of numerous Phase II trials testing neoadjuvant chemotherapy. The crucial points in the next phase of trials include: patient selection, whether radiotherapy can be omitted altogether and whether chemotherapy can be used to augment the initial response to chemoradiotherapy. Finally, with the emergence of Magnetic Resonance Tumour Regression Grade a reliable method for assessing response after initial chemoradiotherapy, we ask if this can be used to drive the use of further sele…

Male0301 basic medicineOncologymedicine.medical_specialtyConsensusColorectal cancermedicine.medical_treatmentRisk AssessmentDisease-Free SurvivalSession (web analytics)law.invention03 medical and health sciencesClinical Trials Phase II as Topic0302 clinical medicineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CaremedicineHumansPreoperative chemotherapyChemotherapyProctectomyRectal Neoplasmsbusiness.industryGastroenterologyPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisNeoadjuvant TherapyRadiation therapyTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisFemaleAugmentbusinessChemoradiotherapyColorectal Disease
researchProduct

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

2019

Abstract Introduction Quality of life (QoL) of comorbid patients with pulmonary malignancies is a key issue in considering fractionated stereotactic body radiotherapy (SBRT) indication. This study investigates the early impact of SBRT on QoL. Methods One hundred patients with pulmonary lesions were treated with SBRT from February 2011 to December 2014 within the prospective, monocenter, phase II STRIPE trial. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core module (EORTC QLQ-C30) and the QLQ-LC13 lung cancer-specific questionnaire were used to evaluate QoL before, 2 and 7 weeks after SBRT, then every 3 months for 2 years. We report on the ana…

Male0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyLung NeoplasmsHealth StatusRadiosurgeryEmotional function03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesAgedLungbusiness.industryCancerPrognosismedicine.diseasehumanitiesKarnofsky index030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCharlson comorbidity indexQuality of LifeFemaleDose Fractionation RadiationbusinessStereotactic body radiotherapyFollow-Up StudiesJournal of Thoracic Oncology
researchProduct

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

2019

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The…

MaleBest practice guidelinesColorectal cancermedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEMedical Oncology030218 nuclear medicine & medical imagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARadiology Nuclear Medicine & Medical ImagingChemoradiotherapyCytoreduction Surgical ProceduresHematologyMiddle AgedOPEN-LABELTotal mesorectal excisionNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleLife Sciences & Biomedicinemedicine.medical_specialtyOrgan preservationLOCAL RECURRENCEAreas of uncertaintiesCOURSE PREOPERATIVE RADIOTHERAPYAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicine;03 medical and health sciencesLow rectal cancerRADIATION-THERAPYmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsEXTRAMURAL VASCULAR INVASIONNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTask forceAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicineTOTAL MESORECTAL EXCISIONRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseColorectal cancerPersonalized medicineClinical trialRadiation therapyPersonalized medicinebusiness
researchProduct

Complications in Craniovertebral Junction Instrumentation: Hardware Removal Can Be Associated with Long-Lasting Stability. Personal Experience

2017

Background The causes of craniovertebral junction (CVJ) instabilities include trauma, rheumatological diseases, tumors, infections, congenital malformations, and degenerative disease processes; these complex pathologies often require CVJ instrumentation. Hardware complications were analyzed in a personal series of 48 treated patients. In light of the analysis of very unusual radiological and clinical findings, the authors tried to better investigate the related mechanisms and to reach possible useful conclusions. Methods In a series of 48 patients who underwent CVJ instrumentation and fusion procedures in our Institution, we describe three cases of hardware failure, due to: (1) infection; (…

MaleBone ScrewsOccipito-cervical fusionOccipito cervical fusion030218 nuclear medicine & medical imagingPostoperative Complications0302 clinical medicineDegenerative diseaseMedicineAxis Cervical VertebraBone infections; Craniovertebral junction; Occipito-cervical fusion; Screwing; Wiring; Surgery; Neurology (clinical)EncephaloceleMedulla OblongataWiringSettore MED/27 - NeurochirurgiaCraniovertebral junctionCongenital malformationsMiddle AgedDecompression SurgicalMagnetic Resonance ImagingBone infectionsProsthesis FailureAtlanto-Axial JointRadiological weaponScrewingComputer hardwareBone WiresJoint InstabilityLong lastingProsthesis-Related InfectionsAdolescentAntineoplastic AgentsBone NeoplasmsCongenital Abnormalities03 medical and health sciencesOdontoid ProcessHumansInstrumentation (computer programming)Device RemovalRadiotherapybusiness.industrymedicine.diseaseRadiographyAtlanto-Occipital JointSpinal FusionSurgeryNeurology (clinical)Tomography X-Ray Computedbusiness030217 neurology & neurosurgeryPlasmacytoma
researchProduct

Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images

2018

International audience; PURPOSE:To evaluate the dose distribution of additional radioactive seeds implanted during salvage permanent prostate implant (sPPI) after a primary permanent prostate implant (pPPI).METHODS AND MATERIALS:Patients with localized prostate cancer were primarily implanted with iodine-125 seeds and had a dosimetric assessment based on day 30 postimplant CT (CT1). After an average of 6 years, these patients underwent sPPI followed by the same CT-based evaluation of dosimetry (CT2). Radioactive seeds on each CT were detected. The detected primary seeds on CT1 and CT2 were registered and then removed from CT2 referred as a modified CT2 (mCT2). Dosimetry evaluations (D90 and…

MaleBrachytherapy[SDV.CAN]Life Sciences [q-bio]/CancerDose distribution[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology030218 nuclear medicine & medical imagingIodine Radioisotopes03 medical and health sciencesProstate cancer0302 clinical medicineProstateDosimetryIodine seedsmedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometrySalvage TherapyPrimary permanentSalvage brachytherapyProstate cancerbusiness.industryProstateProstatic NeoplasmsProstate implantRadiotherapy Dosagemedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTomography X-Ray ComputedbusinessNuclear medicineSalvage brachytherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Model-Based Dose Calculation Algorithms for Brachytherapy Dosimetry

2019

The purpose of this study was to review the limitations of dose calculation formalisms for photon-emitting brachytherapy sources based on the American Association of Physicists in Medicine (AAPM) Task Group No. 43 (TG-43) report and to provide recommendations to transition to model-based dose calculation algorithms. Additionally, an overview of these algorithms and approaches is presented. The influence of tissue and seed/applicator heterogeneities on brachytherapy dose distributions for breast, gynecologic, head and neck, rectum, and prostate cancers as well as eye plaques and electronic brachytherapy treatments were investigated by comparing dose calculations based on the TG-43 formalism …

MaleCancer ResearchDose calculationmedicine.medical_treatmentBrachytherapyBrachytherapyDose distribution030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometryHead and neckSocieties MedicalPhotonsTask groupbusiness.industryRadiotherapy Planning Computer-AssistedRadiotherapy DosageModels Theoretical3. Good healthFormalism (philosophy of mathematics)Oncology030220 oncology & carcinogenesisPractice Guidelines as TopicFemalebusinessAlgorithmAlgorithmsSeminars in Radiation Oncology
researchProduct

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

2017

Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan–Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair agreement was found between mrTRG and pT…

MaleCancer ResearchPathologySURGERYColorectal cancerACCURACYmedicine.medical_treatmentMagnetic resonance tumour regression gradePREOPERATIVE CHEMORADIATIONKaplan-Meier EstimateTHERAPY030218 nuclear medicine & medical imaging0302 clinical medicineInterquartile rangeRectal cancerNeoadjuvant therapyAged 80 and overCOMPLETE RESPONSEmedicine.diagnostic_testMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleRadiologyLife Sciences & BiomedicineRADIOTHERAPYAdultmedicine.medical_specialtyCytodiagnosismagnetic resonance tumour regression gradeDisease-Free Survival03 medical and health sciencesClinical Trials Phase II as TopicmedicinePathological tumour regression gradeHumansOncology & Carcinogenesisrectal cancerPathologicalpathological tumour regression gradeAgedNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTOTAL MESORECTAL EXCISIONMagnetic resonance imagingChemoradiotherapy AdjuvantRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseClinical trialRadiation therapyClinical StudyFOLLOW-UPbusiness1112 Oncology And CarcinogenesisChemoradiotherapy
researchProduct

Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.

2017

IF 2.755; International audience; To assess the risk of second primary malignancy (SPM) in patients with gastric mucosa-associated lymphoid tissue (MALT) Lymphoma (GML), we included 175 patients with GML in the present study. The incidence of SPM in the general population, used for reference, was determined from the French network of cancer registries. During the 1442.9 patient-years of follow-up, 29 patients were diagnosed with incident SPM, including five patients diagnosed with gastric cancer (20.1/1000 patient-years). An increased incidence of SPM was observed in patients with GML (standardized incidence ratios [SIR]: 1.71 [1.14-2.45]) compared to the general French population especiall…

MaleCancer ResearchPathologymedicine.medical_treatmentGastroenterology[ SDV.CAN ] Life Sciences [q-bio]/CancerMALT0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy Protocolsalkylating agentsAged 80 and overeducation.field_of_studyrituximab plus chlorambucilbiologyIncidence (epidemiology)Incidencet(11.18) translocationNeoplasms Second PrimaryHematologyMiddle Aged3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleImmunotherapymedicine.medical_specialtyPopulation[SDV.CAN]Life Sciences [q-bio]/CancerMalignancy03 medical and health sciencesStomach NeoplasmsInternal medicinemedicineGastric mucosaHumanseducationAgedNeoplasm StagingRetrospective StudiesChemotherapyRadiotherapybusiness.industryfungiCancerLymphoma B-Cell Marginal ZoneHelicobacter pylorimedicine.diseasebiology.organism_classificationLymphomaOriginal Article: ClinicalbusinessFollow-Up Studies
researchProduct

Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: A single institutional experience of dose…

2013

Aims To evaluate long-term late side effects, clinical and biochemical relapse in non-metastatic prostate cancer patients treated with dose escalation, from 74 to 78 Gy, by means of three dimensional conformal radiation therapy. Materials and Methods Clinical data of 125 patients with prostate cancer who underwent three-dimensional conformal radiation therapy were retrospectively evaluated. All patients were stratified, according to the NCCN classification, in low, intermediate and high risk, and all of them showed histologically proven adenocarcinoma stage T1–T3 with at least 2 years of follow-up. Late toxicity was analyzed using a modified Radiation Therapy Oncology Group toxicity scale. …

MaleCancer ResearchThree dimensional conformal radiation therapyUrinary BladderUrogenital SystemKaplan-Meier EstimateAdenocarcinomaDisease-Free SurvivalBiomarkers Tumor80 and overHumansLate toxicity; Local control; Prostate cancer; Radiation therapy; Three dimensional conformal radiation therapy; Adenocarcinoma; Aged; Aged 80 and over; Biomarkers Tumor; Disease-Free Survival; Gastrointestinal Tract; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Conformal; Rectum; Retrospective Studies; Urinary Bladder; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiation InjuriesAgedNeoplasm StagingRetrospective StudiesAged 80 and overProstate cancerTumorRadiotherapyConformalMedicine (all)RectumProstatic NeoplasmsRadiotherapy DosageGeneral MedicineMiddle AgedProstate-Specific AntigenRadiation therapyGastrointestinal TractItalyOncologyLocal controlRadiotherapy ConformalLate toxicityBiomarkers
researchProduct